Found: 5
Select item for more details and to access through your institution.
Quarterly intravenous ibandronate for postmenopausal osteoporosis.
- Published in:
- Women's Health (17455057), 2008, v. 4, n. 3, p. 219, doi. 10.2217/17455057.4.3.219
- By:
- Publication type:
- Article
Efficacy and Safety of Oral Weekly Ibandronate in the Treatment of Postmenopausal Osteoporosis.
- Published in:
- Journal of Clinical Endocrinology & Metabolism, 2003, v. 88, n. 10, p. 4609, doi. 10.1210/jc.2003-022029
- By:
- Publication type:
- Article
Efficacy and safety of oral weekly ibandronate in the treatment of postmenopausal osteoporosis.
- Published in:
- 2003
- By:
- Publication type:
- journal article
Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial.
- Published in:
- 2002
- By:
- Publication type:
- journal article
Significant Differential Effects of Alendronate, Estrogen, or Combination Therapy on the Rate of Bone Loss after Discontinuation of Treatment of Postmenopausal Osteoporosis.
- Published in:
- Annals of Internal Medicine, 2002, v. 137, n. 11, p. 875, doi. 10.7326/0003-4819-137-11-200212030-00008
- By:
- Publication type:
- Article